Testing a helium-oxygen gas mix for breathlessness in heart failure with obesity
Tests a helium-oxygen gas mix during exercise in adults with heart failure and obesity.
Plain-language title generated from the registry record
Registry title: Targeting Breathing Limitations to Improve Functional Outcomes in HFpEF
Key facts
- Where
- Dallas, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 55 and 90 years old?
Source: NCT05723679, who can take part
Where in United States
- UT Southwestern Medical CenterDallas, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Texas Southwestern Medical Center
- Trial code
- NCT05723679
- Record updated
- 7 May 2026
- Original description
The overall purpose of this study is to investigate whether pulmonary limitations that increase the oxygen (O2) cost of breathing impact dyspnea on exertion (DOE) and peak exercise capacity in patients with HFpEF and obesity. As per investigator's hypothesis, obesity is likely a significant contributor to DOE and exercise intolerance in patients with HFpEF.Read full original descriptionShow less
Targeting Breathing Limitations to Improve Functional Outcomes in Heart Failure With Preserved Ejection Fraction (HFpEF)
The overall purpose of this study is to investigate whether pulmonary limitations that increase the oxygen (O2) cost of breathing impact dyspnea on exertion (DOE) and peak exercise capacity in patients with HFpEF and obesity. As per investigator's hypothesis, obesity is likely a significant contributor to DOE and exercise intolerance in patients with HFpEF.
Inclusion: signs and symptoms of heart failure; an ejection fraction > 0.50; objective evidence of diastolic dysfunction. elevated biomarkers (NT-proBNP >300 ng/dl) or HF hospitalization; healthy volunteers.
Exclusion: phosphodiesterase type 5 (PDE5) inhibitor use; Atrial fibrillation with poorly controlled heart rate; severe valvular disease; severe Chronic obstructive pulmonary disease (COPD); Chronic kidney disease (CKD) 4 or higher; age < 55 years; BMI > 50 kg/m2; any restriction of ambulation and mobility.